Anneke Hesseling, MD, PhD  is  a Distinguished Professor in Paediatrics and Child Health, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, and Director of the Desmond Tutu TB Centre. 

She holds the first South African National Research Foundation SARChi chair in Paediatric Tuberculosis.   She chairs the NIH-funded International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) TB Scientific Committee and serves on several WHO TB treatment advisory  and guideline groups.  She has a special interest in TB and RR-TB prevention and treatment  in children and other priority populations

Lindsay McKenna is one of the co-directors of the tuberculosis (TB) project at Treatment Action Group (TAG), a research and policy advocacy organization based in New York. Lindsay leads TAG's advocacy to accelerate the development of and access to novel TB treatment technologies. Lindsay supports work across TAG's TB program to advocate for TB research funding before governments and other donors; promote community engagement in TB research; and facilitate access to the benefits of scientific progress. 

Elin Svensson has a degree in Chemical Engineering (2011) and a PhD in Pharmaceutical Sciences (2016). She currently holds a position as Professor in Pharmacometrics at Department of Pharmacy, Uppsala University, Sweden, and is also affiliated with Radboud University Medical Center, Nijmegen, The Netherlands. She is working with research connected to development of novel anti-tuberculosis drug regimens within the PanACEA and UNITE4TB consortia. Elin is also active in the pediatric clinical trials and a regular advisor for WHO in questions related to dosing of anti-tuberculosis drugs.s here

Finny Fitry Yani is a lecturer and pediatric consultant respirology practitioner from Faculty of Medicine Universitas Andalas, with a primary focus on pediatric tuberculosis in Indonesia.

She has over a decade of experience as a consultant pediatric tuberculosis in Indonesian National TB program. In 2019, she joined with Indonesian tuberculosis Research Network (JetSet TB) and in 2020 become one of National Expert TB Committee She also has been developed several pediatric TB guidelines along with TB working group from Indonesia.

Dr. Paradkar is a Pediatrician, Senior Manager-TB Research, and an early-stage investigator for the Johns Hopkins Center for Infectious Diseases in India (JH-CIDI), based at the BJ Government Medical College-Johns Hopkins University Clinical Research Site (BJGMC-JHU-CRS), Pune, India. He is the Operations Working Group Chair for Regional, Prospective, Observational Research in Tuberculosis (RePORT India) Consortium and implements RePORT studies at the site.

He is an IMPAACT Network Young Investigator, Commonwealth Masters Public Health Scholar, and a RePORT International Postdoctoral Fellow.

Dr. Grace Montepiedra earned their B.S. and M.S. degrees from the University of the Philippines, Diliman, and a Ph.D. in Statistics from the University of Minnesota–Twin Cities. Recently retired as Senior Research Scientist at the Harvard T.H. Chan School of Public Health, they have spent over 20 years as lead statistician for the International Maternal, Pediatric and Adolescent AIDS Clinical Trials Network. Their work has focused on designing, monitoring, and analyzing TB prevention and treatment trials, including studies on novel MDR-TB drugs in children. Dr. Montepiedra has served on expert panels, authored consensus papers advocating earlier inclusion of children and pregnant people in TB trials, and advanced innovative statistical methods for TB research.

Dr. Lewis is board certified in Pediatric Infectious Diseases with a special interest in the care and treatment of children living with HIV and has worked in this field since the early 1990s.  She began working with the Product development, Quality, Costing, and Regulatory Affairs (PQCRA) Team at Clinton Health Access Initiative in June 2016 and became Director, Clinical and Regulatory Affairs in December 2018.  In this capacity, she provides clinical and regulatory advice to other CHAI teams and to external partners in clinical care, research, industry, and normative bodies.  Her work has focused on advising stakeholders on appropriate development and regulatory pathways for drugs, primarily antiretrovirals, and making new, high-quality pediatric formulations available for use in low- and middle-income countries. She maintains an active role in global pediatric drug prioritization activities with the WHO as an observer on the Pediatric Antiviral Working Group (PAWG).  Prior to joining CHAI, Dr. Lewis served as Medical Team Leader and was the senior pediatrician in the Division of Antiviral Products at the U.S. Food and Drug Administration (1999-2016).

Dr Pauline Howell is a Deputy Director at the Clinical HIV Research Unit (CHRU) and Research Site Leader at both the Sizwe Tropical Disease Hospital in Johannesburg and the Isango Lethemba TB Research Unit in Gqeberha, both in South Africa. With 12 years’ experience as a clinical trial investigator in tuberculosis, Dr Howell has contributed to landmark drug-resistant tuberculosis (DR-TB) trials, including STREAM, Nix, ZeNix, IMPAACT1108 and BEAT-Tuberculosis which all led to WHO guideline changes. She has been a principal investigator for paediatric DR-TB trials for bedaquiline, delamanid and pretomanid as well as a vice-chair of several paediatric protocol teams.

Dr Howell is a member of the IMPAACT TB Scientific Committee, and the South African National Clinical Advisory Committee, a ministerial committee that advises the National Department of Health on treatment for DR-TB. Dr Howell is committed to developing shorter, safer, and more effective DR-TB treatments for all patients, including children and pregnant women.

Tim R. Cressey, MSc, PhD, has been actively involved in clinical research studies on infectious diseases for over 24 years, primarily focusing on clinical pharmacology in maternal and child health. He has led numerous clinical pharmacokinetic studies in adolescents, children, pregnant women, and newborns. Currently, he severs as the Research Director at the AMS-PHPT Research Unit based at the at the Faculty of Associated Medical Sciences, Chiang Mai University, Thailand, and the CRS-Site Leader of the NICHD-IMPAACT site at Chiangrai Prachanukroh Hospital, Thailand. Dr. Cressey has contributed extensively to global health initiatives, serving as a member of the World Health Organization’s Pediatric Antiretroviral Drug Optimization (PADO) Working Group, where he held the position of Co-Chair from 2016 to 2020. This group provides critical guidance on pediatric dosing recommendations for the WHO Antiretroviral Treatment Guidelines. More recently, he has been leading the WHO-GAP-f Clinical Research Working Group to accelerate the development of pediatric formulations to treat HIV, TB, hepatitis C virus and antimicrobial resistance.

Dr Louvina van der Laan is a paediatric clinician and pharmacometrician based at Stellenbosch University’s Desmond Tutu TB Centre. She is one of very few clinician-pharmacometricians worldwide and the only formally trained in South Africa, bridging clinical care with advanced mathematical modelling. Her research focuses on optimising drug dosing for children with tuberculosis and HIV, and her work has directly informed World Health Organization dosing guidelines. She has published extensively in leading journals, serves as Principal Investigator on international pharmacokinetic trials, and supervises PhD students in pharmacometrics. As a member of the WHO Tuberculosis Technical Advisory Group, she contributes to global child health policy. Her long-term vision is to develop physiologically based models to improve paediatric care globally.

Nicole A. Montañez, MSW is a public health mixed methods researcher and doctoral student at UCLA’s Fielding School of Public Health, specializing in Health Psychology. Within the CHEETA initiative, she leads site assessments and global operational strategy to accelerate pediatric TB research and reduce treatment delays. Nicole brings over a decade of experience in HIV, TB, and cancer clinical trials, with expertise in registrational trial management, protocol operationalization, and community-centered implementation. She has contributed to trials including IMPAACT 1093, 2015, 2016, 2020, and 2034, supported regulatory submissions, and serves as an Investigator of Record and TBSC Mentored Investigator within the IMPAACT Network. Nicole sits on TB-focused scientific committees and bridges biomedical and behavioral sciences to inform equitable, participant-centered research. She is passionate about integrating social determinants and trauma-informed approaches into trial design, particularly in contexts of HIV, TB, and early life adversity.